Sterling's oral milrinone
Executive Summary
At its May 6 annual meeting, the firm announced it expects to complete "within the near future" analysis of the results of three major multicenter blinded studies of Coratrope. If favorable, the results "will form the data base for an NDA submission for oral Coratrope some time later this year," Sterling said. An NDA for the injectable form is pending at FDA.